As patients transition from treatment to routine monitoring, clinicians play a crucial part in detecting recurrence early, supporting wellbeing, and guiding patients through survivorship.

In the latest episode of our podcast Melanoma Insights for Professionals, we explore the essential role of follow-up care in melanoma management.

Our multidisciplinary experts provide an engaging and practical discussion to help strengthen your approach to melanoma follow-up care and covers:

• why follow-up schedules vary and how clinicians tailor them
• stage-specific approaches for all stages of melanoma
• the role of dermatological surveillance and patient education
• supporting psychological wellbeing, including managing scanxiety.

This podcast is suitable for Surgeons, Dermatologists, Skin Cancer GPs, GPs, Nurses and other health professionals.

If you require a Statement of Completion for your CPD records, please listen to this podcast via the the Melanoma Education Portal.

SPEAKERS

• A/Prof Robyn Saw - Surgical Oncologist, Melanoma Institute Australia | Head of Department in Melanoma and Surgical Oncology, Royal Prince Alfred Hospital | Associate Professor in Surgery, The University of Sydney
• Dr Mary-Ann El Sharouni - Dermatologist, Melanoma Institute Australia and Sydney Melanoma Diagnostic Centre, Royal Prince Alfred Hospital
• Claire Gore - Senior Clinical Psychologist, Melanoma Institute Australia

RESOURCES

• MIA’s Patient Resources (including Guides like Melanoma Prevention and Early Detection Guide and Patient Fact Sheet such as Scanxiety and How to cope with the fear of melanoma returning)

• Cancer Council’s SunSmart Global UV app

• 
  

Please note that this presentation was accurate at the time of recording (November 2025) but may not reflect the rapidly evolving treatment landscape and approvals in Australia.

MIA’s Education Program is proudly supported through unrestricted educational grants from BMS, MSD and HEINE.

As melanoma in situ (MIS) diagnoses rise, concerns about overdiagnosis are growing — with real implications for patients, clinicians and the health system.

In this episode of our podcast Melanoma Insights for Professionals, experts from dermatology, pathology, psychology and research come together to explore the drivers of overdiagnosis, the psychological impact of an MIS label, and the role of emerging diagnostic tools and data.

This podcast is suitable for multidisciplinary specialist, primary care physicians and other healthcare professionals.

SPEAKERS

• Dr Peter Ferguson - Pathologist, Royal Prince Alfred Hospital and Melanoma Institute Australia
• Dr Christoph Sinz - Confocal Microscopy Dermatologist, Melanoma Institute Australia
• Claire Gore - Senior Clinical Psychologist, Melanoma Institute Australia
• Dr Ismael Vergara - Senior Computational Biologist, Melanoma Institute Australia | Adjunct Senior Lecturer, The University of Sydney

RESOURCES

• MIA’s Patient Guides (e.g. Your Guide to Melanoma In-Situ)
• MIA’s Patient Fact Sheets (e.g. Scanxiety)

REFERENCES

• Bjørch MF, Gram EG, Brodersen JB Overdiagnosis in malignant melanoma: a scoping review BMJ Evidence-Based Medicine 2024;29:17-28.
• Cramb SM, Duncan EW, Aitken JF, Soyer HP, Mengersen KL, Baade PD. Geographical patterns in melanoma incidence across Australia: Can thickness differentials reveal the key drivers? Ann Cancer Epidemiol 2020;4:11
• Daniel Lindsay, Katy J L Bell, Catherine M Olsen, David C Whiteman, Thanya Pathirana, Louisa G Collins, Estimating the magnitude and healthcare costs of melanoma in situand thin invasive melanoma overdiagnosis in Australia British Journal of Dermatology, 2024;191(6): 906–913,
• Patel VR, Roberson ML, Pignone MP, Adamson AS. Risk of Mortality After a Diagnosis of Melanoma In Situ. JAMA Dermatol.2023;159(7):703–710.

• 
  

Please note that this podcast was accurate at the time of recording (August 2025) but may not reflect the rapidly evolving treatment landscape and approvals in Australia.

MIA’s Education Program is proudly supported through unrestricted educational grants from Bristol Myers Squibb, MSD and HEINE.

In this episode, we explore how melanoma risk prediction tools are transforming clinical decision-making for newly diagnosed patients. These tools, developed by Melanoma Institute Australia and freely available at melanomarisk.org.au, help clinicians tailor care and improve outcomes.

Our multidisciplinary experts provide practical guidance on using tools to predict sentinel node metastasis, recurrence risk and more. Through real-world case examples and expert insights, this episode offers valuable strategies for integrating personalised risk assessment into your practice.

This podcast is suitable for multidisciplinary specialists, primary care physicians and other healthcare professionals.

Resources:

• Melanoma Risk Prediction Calculators
• MIA's Patient Resources
• Melanoma Education Portal

Speakers:

• Prof Anne Cust - Cancer Epidemiologist and Faculty Member, Melanoma Institute Australia | Interim Director, Daffodil Centre | Chair, Cancer Council National Skin Cancer Committee

• A/Prof Alex Varey - Plastic and Reconstructive Surgeon, Melanoma Institute Australia and Westmead Hospital | Clinical Associate Professor, The University of Sydney

• A/Prof Linda Martin - Director of Dermatology Services, Melanoma Institute Australia | Staff Specialist, Sydney Children’s Hospital | Associate Professor of Dermatology, University of NSW

Please note that this podcast was accurate at the time of recording (August 2025) but may not reflect the rapidly evolving treatment landscape and approvals in Australia.

MIA’s Education Program is proudly supported through unrestricted educational grants from BMS, MSD and HEINE.